UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

Journal of clinical pharmacology, 2008-04, Vol.48 (4), p.475-484

2008

Volltextzugriff (PDF)

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Cardiovascular diabetology, 2024-02, Vol.23 (1), p.63-63, Article 63

2024

Volltextzugriff (PDF)

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Nature medicine, 2022-03, Vol.28 (3), p.591-598

2022

Volltextzugriff (PDF)

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

Cardiovascular diabetology, 2022-08, Vol.21 (1), p.1-163, Article 163

2022

Volltextzugriff (PDF)

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy

Journal of clinical pharmacology, 2012-06, Vol.52 (6), p.789-797

2012

Volltextzugriff (PDF)

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis

The Journal of thoracic and cardiovascular surgery, 2013-04, Vol.145 (4), p.1077-1082.e4

2013

Volltextzugriff (PDF)

Mortality Benefit With Prasugrel in the TRITON―TIMI 38 Coronary Artery Bypass Grafting Cohort: Risk-Adjusted Retrospective Data Analysis

Journal of the American College of Cardiology, 2012-07, Vol.60 (5), p.388-396

2012

Volltextzugriff (PDF)

Comparison of Speed of Onset of Platelet Inhibition After Loading Doses of Clopidogrel Versus Prasugrel in Healthy Volunteers and Correlation With Responder Status

The American journal of cardiology, 2007-07, Vol.100 (2), p.331-336

2007

Volltextzugriff (PDF)

Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method

Drug metabolism and disposition, 2007-06, Vol.35 (6), p.917-921

2007

Volltextzugriff (PDF)

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

Journal of cardiovascular pharmacology, 2006-03, Vol.47 (3), p.377-384

2006

Volltextzugriff (PDF)

90-LB: Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study

JAMA cardiology, 2018-05, Vol.3 (5), p.401

2018

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38

Journal of clinical pharmacology, 2009-08, Vol.49 (8), p.984-998

2009

Volltextzugriff (PDF)

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects

Journal of cardiovascular pharmacology, 2007-03, Vol.49 (3), p.167-173

2007

Volltextzugriff (PDF)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

The Lancet (British edition), 2021-11, Vol.398 (10313), p.1811-1824

2021

Volltextzugriff (PDF)

Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort

Journal of the American College of Cardiology, 2012-07, Vol.60 (5), p.388-396

2012

Volltextzugriff (PDF)

COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.1628-1628

2023

Volltextzugriff (PDF)

Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis

Journal of cardiovascular pharmacology and therapeutics, 2007-09, Vol.12 (3), p.205-212

2007

Volltextzugriff (PDF)

Clopidogrel poor responders: An objective definition based on Bayesian classification

Platelets (Edinburgh), 2007-01, Vol.18 (6), p.428-435

2007

Volltextzugriff (PDF)

Effect of Intracluster Correlation on the R-Square Statistic

Biometrical journal, 1999-10, Vol.41 (6), p.697-709

1999

Volltextzugriff (PDF)

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

Circulation (New York, N.Y.), 2008-10, Vol.118 (suppl_18)

2008

Volltextzugriff (PDF)

Abstract 12636: Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events: Insights from the ACCELERATE Trial

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A12636-A12636

2018

Volltextzugriff (PDF)

Effect of Intracluster Correlation on theR-Square Statistic

Biometrical journal, 1999-10, Vol.41 (6), p.697-709

1999

Volltextzugriff (PDF)

Theory and Methods: Hypothesis Testing in Two-Stage Cluster Sampling

Australian & New Zealand journal of statistics, 1998-09, Vol.40 (3), p.335-344

1998

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(52)

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(32)
Humans
(24)
Male
(18)
Cardiovascular System & Cardiology
(17)
Female
(17)
Middle Aged
(17)
Cardiac & Cardiovascular Systems
(16)
Aged
(14)
Prasugrel Hydrochloride
(14)
Ticlopidine - Analogs & Derivatives
(12)
Adult
(10)
Diabetes
(9)
Diabetes Mellitus
(9)
Biological And Medical Sciences
(8)
Double-Blind Method
(8)
Pharmacology & Pharmacy
(8)
Prasugrel
(8)
Mathematics
(7)
Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis

Mortality Benefit With Prasugrel in the TRITON―TIMI 38 Coronary Artery Bypass Grafting Cohort: Risk-Adjusted Retrospective Data Analysis

Comparison of Speed of Onset of Platelet Inhibition After Loading Doses of Clopidogrel Versus Prasugrel in Healthy Volunteers and Correlation With Responder Status

Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

90-LB: Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort

COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4

Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis

Clopidogrel poor responders: An objective definition based on Bayesian classification

Effect of Intracluster Correlation on the R-Square Statistic

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

Abstract 12636: Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events: Insights from the ACCELERATE Trial

Effect of Intracluster Correlation on theR-Square Statistic

Theory and Methods: Hypothesis Testing in Two-Stage Cluster Sampling

Suchergebnisse filtern